SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant post-earnings reaction, as its Q1 guidance, despite some strong Q4 results, has triggered a sharp sell-off and community debate. Many view this as a healthy correction or a buying opportunity, emphasizing the company's long-term turnaround strategy and strategic national importance with government backing. Conversely, others point to ongoing competitive pressures, high valuation, and future sales traction not expected until 2026/2027, leading to a bearish outlook.

RYVYL Inc. is a financial technology company that develops software platforms and tools that are focused on providing global payment acceptance and disbursement capabilities. It offers an innovative payment platform-as-a-service that redefines global payment solutions, enabling seamless business-to-business, consumer-to-business, and peer-to-peer transactions worldwide. The company leverages advanced electronic payment technology to deliver seamless financial solutions across global markets. It operates through two geographical segments: North America and International. The company was founded on April 10, 2007 and is headquartered in San Diego, CA.

Ryvyl Inc

RVYL is actively trending as the community closely monitors developments surrounding its merger with Roundtable and a recent reverse stock split. The low public float and progression towards Nasdaq compliance, alongside new strategic partnerships such as a notable deal with The Hockey News, are fueling discussions about potential short squeeze opportunities. Traders are keenly debating the company's post-merger valuation and the vision for its Web3 digital media and Bitcoin treasury ecosystem.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending due to significant community discussion surrounding its MASH treatment, pemvidutide, which holds Breakthrough Therapy Designation from the FDA and is perceived as a "best-in-class" asset in the booming obesity and liver disease market. Investors are keenly anticipating a potential partnership or buyout, driven by the drug's differentiated profile, the new CEO's M&A experience, and high short interest, leading to widespread speculation of a substantial re-rating and short squeeze.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is generating significant buzz due to its extremely low share float, fueling intense speculation around a potential short squeeze. While many in the community are anticipating a rapid, parabolic breakout, others caution against a pump-and-dump scheme, citing the company's publicly acknowledged strategic review and discontinued operations. This dynamic has positioned SNSE as a highly volatile micro-cap, attracting traders focused on short-term, speculative price movements.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano is trending following its announced merger with Corvex, an AI cloud computing firm that secured a long-term deployment of NVIDIA H200 GPUs for its infrastructure. The community is sharply divided, with many anticipating a significant short squeeze driven by the low share float and AI sector interest, while others caution that the NVIDIA connection is overblown and fear potential dilution.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing intense market attention following impressive weekly prescription data for its oral Wegovy, which significantly surpassed analyst expectations. Community discussion highlights the "magic pill" as a transformative advantage, solidifying NVO's leadership in the rapidly expanding GLP-1 sector and drawing comparisons to top-tier valuations. This momentum, amplified by confidence in its market position and clarity on tariff protections, is fueling widespread bullish sentiment.

Movement Network is a secure and scalable blockchain designed to make Move programming accessible to developers everywhere. With high-performance execution and security, Movement delivers the infrastructure for the next generation of decentralized applications and unleashes opportunity and financial empowerment for anyone, anywhere.  $MOVE is the native token of Movement Network, for transaction fees and staking to secure the network. The Movement M1 (Layer 1) Network is powered by the Move programming language, unleashing opportunity, accessibility, and financial empowerment for anyone, anywhere.

MarketMove

MarketMove is trending significantly after its merger partner, Corvex, announced a long-term NVIDIA H200 GPU deployment with an AI-driven battery technology provider. This key development positions the combined entity as a player in secure AI infrastructure, sparking widespread community excitement about its enhanced growth prospects and strategic pivot into high-performance AI platforms. Investors are closely following this shift, anticipating continued momentum fueled by interest in cutting-edge technology.

BitGo Holdings, Inc. provides cryptocurrency custody solutions. It offers self-custody wallet, qualified custody, liquidity and prime, and infrastructure-as-a-service. The company was founded by Michael Belshe in 2013 and is headquartered in Palo Alto, CA.

BitGo Holdings Inc. - Ordinary Shares - Class A

BTGO is actively discussed post-IPO, with the community debating its initial market performance. While some are concerned by early dips, many are optimistic, citing its unique position as a 'pure-play' institutional crypto custodian with strong regulatory standing and a tight share float as potential drivers for long-term appreciation.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending after its recent Q3 earnings exceeded expectations, highlighting strong user growth and improved margins, alongside analyst upgrades that underscore long-term potential from AI-driven features and new content like music videos. However, recent subscription price increases and reports of a significant data leak are active community talking points. Many investors are also observing the stock's perceived correlation with broader tech market and Netflix movements, adding to its current volatility.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending as its consistent strong earnings performance, fueled by robust inside sales and strategic acquisitions, continues to impress. The community highlights its unique convenience store model, particularly its popular food offerings, seeing it as a resilient long-term growth and dividend play in the expanding retail sector, despite ongoing discussions about its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

<ul class="summary-bullets"><li>Prasad, who oversees gene therapies in the FDA, told Bloomberg that regulation needs to evolve as science develops.</li><li>The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. &nbsp;</li></ul>A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases.Vinay Prasad, who oversees gene therapies in the U.S. Food and Drug Administration, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-31/fda-clears-way-for-faster-personalized-gene-editing-treatments">told</a> Bloomberg that regulation needs to evolve as science develops. Prasad reportedly added that scientific advances like Nobel prize-winning CRISPR gene-editing technology have forced the agency to relax some of its strict rules.The agency is “going to be extremely flexible and work very fast with the scientists who want to bring these therapies to kids who need it,” Prasad told Bloomberg.The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. Prasad expects it will spark interest in developing treatment for rare diseases.<h2 class="st-heading-2">CRISPR’s Potential</h2>CRISPR gene editing is a technology that allows scientists to modify an organism's DNA precisely. It involves a guide RNA that directs a DNA-cutting enzyme to a specific target in the DNA for it to make a cut. The cell's natural repair process either inactivates the gene or allows scientists to insert a new piece of DNA.Earlier this year, an infant named KJ Muldoon, born with a rare genetic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, was successfully treated with a customized CRISPR gene editing therapy by a team at the Children’s Hospital of Philadelphia.The team behind the treatment of the infant is now designing clinical trials that can be used to gain FDA approval with a gene-editing platform that can be tailored for patients with different genetic mutations, Bloomberg reported. The team is asking for FDA permission to start clinical trials for a liver disorder known as phenylketonuria and urea cycle disorders, the report added.These diseases can be treated by editing genes in the liver, a known target for CRISPR, team members told Bloomberg.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ardelyx-shares-soar-premarket-as-ceo-sees-continued-demand-for-blockbuster-drug-ibsrela/cLGqRUcR3Ur">Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 

Equity

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 


UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus

UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV. 

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


BioXcel Therapeutics, Inc. (BTAI) announced on Wednesday that its BXCL501 demonstrated continued effects and consistent benefit with repeat dosing in the treatment of agitation associated with bipolar disorders or schizophrenia in a late-stage trial.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine, marketed by the company as Igalmi. While the primary objective of the trial was to ascertain the safety of the formulation in an at-home setting, the continued effects and consistent benefits observed with repeat dosing in the trial further support the potential of BXCL501 for use in the outpatient setting, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-positive-topline-exploratory">said</a>.Shares of the company rose 3% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> rose from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.BioXcel <a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-sublingual-film-well-tolerated-in-bipolar-schizophrenia-trial-in-at-home-settings/chsU5sURdl5">reported</a> late last month that the drug was well-tolerated in the study. The company said that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration (FDA) slated for the first quarter of 2026 and aimed at expanding the label for Dexmedetomidine in the at-home setting.“These positive results, along with the safety and tolerability data previously announced, reinforce BXCL501’s potential in the at-home setting where there is substantial unmet need with no FDA-approved options currently available,” said BioXcel CEO Vimal Mehta.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.BTAI stock is down by 40% this year and by 59% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-ahead-of-inflation-data/chwkJpfRduc">Dow Futures Edge Lower As Investors Turn Cautious Ahead Of Inflation Data: ORCL, KLAR, HOOD, GME Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study

The company stated that the continued effects and consistent benefits observed with repeat dosing in the trial support the potential of BXCL501 for use in the outpatient setting. 

BioXcel Therapeutics, Inc. (BTAI) on Wednesday said that its late-stage trial evaluating the safety of the company’s BXCL501 as a treatment for agitation associated with bipolar disorders or schizophrenia in the at-home setting met its primary goal of being well-tolerated.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-serenity-home-pivotal-phase-3">said</a> that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration slated for the first quarter of 2026 and aimed at expanding the label for its dexmedetomidine sublingual film called Igalmi in the at-home setting.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_9_42_20_AM_png_54402b6e8c.webp" alt="BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="624" height="65"><figcaption>BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the shares of the company.<stembedurl>https://stocktwits.com/Michael17711771/message/626688937</stembedurl>Another user opined that the study results are very promising long term.<stembedurl>https://stocktwits.com/They_call_me_tater_salad/message/626688733</stembedurl>BioXcel said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.“By meeting its primary endpoint, the SERENITY At-Home Pivotal Phase 3 trial reinforces BXCL501’s potential to be safely used at home like it is already used in the previously FDA approved institutional setting. The unmet medical need in the at-home setting is significant with no FDA-approved treatments,” CEO Vimal Mehta said, while adding that the company believes the total addressable market is “significantly larger” than previously reported.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.The company said that available data demonstrate that treatment with BXCL501 regularly reduced symptoms of agitation throughout the trial. A greater percentage of patients experiencing mild, moderate, or severe agitation had full resolution of symptoms in the BXCL501 arm compared with placebo. Complete analyses of the full data set are ongoing and will be shared in time, the company said.BTAI stock is down by 24% this year and by 57% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later

The company said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.

Fidelity Covington Trust - Fidelity MSCI Health Care Index ETF

Policy uncertainty from Trump

Earnings & guidance

Options / dealer positioning

Liquidity & algos

Markets are reacting to a mix of policy headlines, earnings, and positioning. We want to hear what you think is driving volatility the most right now.

FHLC
Fidelity MSCI Health Care Index ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FHLC News

FHLCFidelity MSCI Health Care Index ETF